Aptinyx Sees Path Forward In DPN With Long-Term Patients

After disappointing top-line Phase II data in diabetic peripheral neuropathy with NYX-2925, Aptinyx says the full dataset shows significance across endpoints in patients four years or more past diagnosis; a second Phase II study in this subgroup is planned.

Neuropathy that is the damage of peripheral nerves that causes pain and loss of sensation in the extremities.
Neuropathy is damage of peripheral nerves that causes pain and loss of sensation in the extremities

Aptinyx Inc. said “stay tuned” after missing the primary and secondary endpoints in a Phase II study of its NMDA modulator NYX-2925 in diabetic peripheral neuropathy (DPN) in January. Now, the Chicago-area firm has released a subgroup analysis showing that DPN patients who have had the disease four years or longer look like optimal subjects for a subsequent Phase II study.

Aptinyx announced on April 18 that a review of the completed Phase II study was presented at the American Pain...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D